Clinical Trial ProgressSignificant progress was made with Aethlon's oncology program, including the first treatment of a patient with the company's Hemopurifier.

Device EfficacyThe Hemopurifier has shown positive results in clearance of hepatitis C virus particles from blood of HCV-positive end-stage renal disease patients undergoing dialysis.

Bears Say

Commercialization ChallengesThe path to commercialization for AEMD remains long and uncertain, leading to a Hold rating.

Revenue ConcernsDespite clinical progress and financial discipline, AEMD did not recognize any revenue during the F3Q25 quarter, and no revenue is forecasted for FY25 or FY26.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

5.43% Insiders

0.70% Mutual Funds

19.30% Other Institutional Investors

74.43% Public Companies and Individual Investors

Detailed Ownership Overview >

AEMD FAQ

What was Aethlon Medical Inc’s price range in the past 12 months?

Aethlon Medical Inc lowest stock price was $1.75 and its highest was $8.44 in the past 12 months.

What is Aethlon Medical Inc’s market cap?

Aethlon Medical Inc’s market cap is $3.54M.

When is Aethlon Medical Inc’s upcoming earnings report date?

Aethlon Medical Inc’s upcoming earnings report date is Jun 26, 2025 which is in 10 days.

How were Aethlon Medical Inc’s earnings last quarter?

Aethlon Medical Inc released its earnings results on Feb 12, 2025. The company reported -$1.04 earnings per share for the quarter, beating the consensus estimate of -$1.627 by $0.587.

Is Aethlon Medical Inc overvalued?

According to Wall Street analysts Aethlon Medical Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Aethlon Medical Inc pay dividends?

Aethlon Medical Inc does not currently pay dividends.

What is Aethlon Medical Inc’s EPS estimate?

Aethlon Medical Inc’s EPS estimate is -1.07.

How many shares outstanding does Aethlon Medical Inc have?

Aethlon Medical Inc has 2,010,721 shares outstanding.

What happened to Aethlon Medical Inc’s price movement after its last earnings report?

Aethlon Medical Inc reported an EPS of -$1.04 in its last earnings report, beating expectations of -$1.627. Following the earnings report the stock price went down -5.431%.

Which hedge fund is a major shareholder of Aethlon Medical Inc?

Currently, no hedge funds are holding shares in AEMD

Aethlon Medical Stock Smart Score

Neutral

Fundamentals

Return on Equity

-160.04%

Trailing 12-Months

Asset Growth

-37.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Aethlon Medical Inc

Aethlon Medical, Inc., a medical technology company, focuses on developing products to diagnose and treat life and organ threatening diseases in the United States. The company develops Aethlon Hemopurifier, a clinical-stage immunotherapeutic device that removes tumor-derived exosomes and life-threatening viruses from the human circulatory system, including removal of COVID-19 virus, associated variants, and related exosomes. Aethlon Medical, Inc. has a collaboration with the University of Pittsburgh Medical Center Hillman Cancer Center for studies related to head and neck cancer. The company was founded in 1999 and is based in San Diego, California.

AEMD Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call indicated a balanced outlook for Aethlon Medical, with significant strides in protocol amendments and cost reduction efforts. However, challenges in patient enrollment and an anticipated increase in operating expenses present ongoing hurdles.Read More>